Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Bone Health and Bone-targeted Therapies for Prostate Cancer

Bone Health and Bone-targeted Therapies for Prostate Cancer Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03148 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Bone Health and Bone-Targeted Therapies (...) for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline , MD 1 x Philip J. Saylor ; , MSc 2 x R. Bryan Rumble ; , MD, MS 3 x Scott Tagawa ; , MD 4 x James A. Eastham ; , MD, MSc 5 x Antonio Finelli ; , MD 6 x Pavan S. Reddy ; , MBA 7 x Terry M. Kungel ; , JD 8 x Merel G. Nissenberg ; and , MBA, MD 9 x Jeff M. Michalski 1 Massachusetts General Hospital, Boston, MA 2 American Society of Clinical Oncology, Alexandria, VA 3 Weill Cornell Medicine, New York, NY 4 Memorial Sloan Kettering Cancer

2020 American Society of Clinical Oncology Guidelines

2. Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations

Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations SPECIAL ARTICLE Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations G. Curigliano 1,2y , D. Lenihan 3y , M. Fradley 4 , S. Ganatra 5 , A. Barac 6 , A. Blaes 7 , J. Herrmann 8 , C. Porter 9 , A. R. Lyon 10 , P. Lancellotti 11 , A.Patel 12 , J.DeCara 13 , J. Mitchell 14 , E. Harrison 15 , J.Moslehi 16 , R.Witteles 17 , M (...) Cardio-oncology Program, Division of Cardiovascular Medicine, Morsani College of Medicine and H. Lee Mof?tt Cancer Center and Research Institute, University of South Florida, Tampa; 5 Cardio-Oncology Program, Lahey Medical Center, Burlington; 6 Cardio-Oncology Program, Medstar Heart and Vascular Institute and MedStar Georgetown Cancer Institute, Georgetown University Hospital, Washington DC; 7 Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis; 8 Mayo Clinic

2020 European Society for Medical Oncology

3. Colorectal cancer

Colorectal cancer Colorectal cancer NICE guideline Published: 29 January 2020 www.nice.org.uk/guidance/ng151 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Colorectal cancer (NG151) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 45Contents Contents Overview 5 Who is it for? 5 Recommendations 6 1.1 Prevention of colorectal cancer in people with Lynch syndrome 6 1.2 Information for people with colorectal cancer 6 1.3

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

4. Optimum Imaging Strategies for Advanced Prostate Cancer

Optimum Imaging Strategies for Advanced Prostate Cancer Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02757 Journal of Clinical Oncology - published online before print January 15, 2020 PMID: Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline , MD 1 x Edouard J (...) Angeles, CA 4 University of California, San Francisco, San Francisco, CA 5 Johns Hopkins Medicine, Owings Mills, MD 6 National Cancer Institute, Bethesda, MD 7 NYU Langone Health, New York, NY 8 University of Cincinnati Medical Center, Cincinnati, OH 9 David Geffen School of Medicine, Los Angeles, CA 10 Mayo Clinic, Rochester, MN 11 The University of Chicago, Chicago, IL 12 Cleveland Clinic, Cleveland, OH 13 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 14 German Cancer Research Center

2020 American Society of Clinical Oncology Guidelines

5. Estrogen and Progesterone Receptor Testing in Breast Cancer

Estrogen and Progesterone Receptor Testing in Breast Cancer Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02309 Journal of Clinical Oncology - published online before print January 13, 2020 PMID: Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP (...) , Queensland, Australia 9 Pathology Queensland, Brisbane, Queensland, Australia 10 MD Anderson Cancer Center, Houston, TX 11 Gemini Group, Ann Arbor, MI 12 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 13 Yale Cancer Center, New Haven, CT 14 Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada 15 University of Saskatchewan, Saskatoon, Saskatchewan, Canada 16 Weill Cornell Medicine, New York, NY 17 IEO, European Institute of Oncology, Istituto di Ricovero e Cura a Carattere

2020 American Society of Clinical Oncology Guidelines

6. Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update

Estrogen and Progesterone Receptor Testing in Breast Cancer Guideline Update EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional changes or corrections may appear in these articles when they appear in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique (...) number given to every article. The DOI will typically appear at the end of the abstract. The DOI for this manuscript is doi: 10.5858/arpa.2019-0904-SA The fi nal published version of this manuscript will replace the Early Online Release version at the above DOI once it is available. © 3 College of American Pathologists 2020 Special Article Estrogen and Progesterone Receptor Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Guideline Update Kimberly H

2020 College of American Pathologists

7. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer CUAJ • February 2020 • Volume 14, Issue 2 © 2020 Canadian Urological Association CUA gUideline 17 Cite as: Can Urol Assoc J 2020;14(2):17-23. http://dx.doi.org/10.5489/cuaj.6384 Published online December 5, 2019 Introduction Metastatic prostate cancer remains an incurable disease. In Canada, approximately 8% of men with prostate cancer are diagnosed (...) de novo with metastatic disease and, in 2018, roughly 1200 men were diagnosed with de novo metastat- ic prostate cancer (PC). 1 The mainstay of treatment for de novo metastatic PC is androgen-deprivation therapy (ADT), which is initially effective in almost all patients. Progression is inevitable, however, heralded by a rise in prostate-specific antigen (PSA), increasing disease burden, and/or worsening symptoms — a disease state called metastatic castration- resistant prostate cancer (mCRPC

2020 Canadian Urological Association

8. Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03022 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Therapy for Stage IV Non (...) –Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update , MD 1 x Nasser H. Hanna ; , MD 2 x Bryan J. Schneider ; , MSPH 3 x Sarah Temin ; , MD 4 x Sherman Baker Jr ; , MD 5 x Julie Brahmer ; , MD, PhD 6 x Peter M. Ellis ; , MD, MBA 7 , 8 x Laurie E. Gaspar ; , MD 9 x Rami Y. Haddad ; , MD 10 x Paul J. Hesketh ; , MD 11 x Dharamvir Jain ; , MD 12 x Ishmael Jaiyesimi ; , MD 13 x David H. Johnson ; , MD 14 x Natasha B. Leighl ; , MD 15 x Tanyanika Phillips ; , MD

2020 American Society of Clinical Oncology Guidelines

9. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Bryan J. Schneider,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson,MD (...) 13 ; Natasha B. Leighl,MD 14 ; Tanyanika Phillips,MD 15 ; Gregory J. Riely, MD, PhD 16 ; Andrew G. Robinson,MD 17 ; Rafael Rosell,MD 18 ; Joan H. Schiller,MD 19 ; Navneet Singh, MD, DM 20 ; David R. Spigel,MD 21 ; Janis O. Stabler 22 ; Joan Tashbar 23 ;and Gregory Masters,MD 24 abstract PURPOSE The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) without driver

2020 Cancer Care Ontario

10. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer

Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02960 Journal of Clinical Oncology - published online before print January 27, 2020 PMID: Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO (...) Guideline , MD, PhD 1 x Panagiotis A. Konstantinopoulos ; , MD 2 x Barbara Norquist ; , MHSc 3 x Christina Lacchetti ; , MD 4 x Deborah Armstrong ; , MD 5 x Rachel N. Grisham ; , PhD 6 x Paul J. Goodfellow ; , MD 7 x Elise C. Kohn ; , MD 8 x Douglas A. Levine ; , MD, MPH 1 x Joyce F. Liu ; , MD 9 x Karen H. Lu ; , MS 10 x Dorinda Sparacio ; and , MD, PhD 11 x Christina M. Annunziata 1 Dana-Farber Cancer Institute, Boston, MA 2 University of Washington Medicine, Seattle, WA 3 American Society of Clinical

2020 American Society of Clinical Oncology Guidelines

11. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer Osimertinib for untreated EGFR mutation-positive non- small-cell lung cancer T echnology appraisal guidance Published: 22 January 2020 www.nice.org.uk/guidance/ta621 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 19Contents Contents 1 Recommendations 4 2 Information about osimertinib 5 Marketing authorisation

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Trastuzumab (Trazimera) - Breast Cancer or Gastric Cancer

Trastuzumab (Trazimera) - Breast Cancer or Gastric Cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2020 Health Canada - Drug and Health Product Register

13. Neratinib maleate (Nerlynx) - adjuvant treatment of women with early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer

Neratinib maleate (Nerlynx) - adjuvant treatment of women with early-stage hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related

2020 Health Canada - Drug and Health Product Register

14. Talazoparib (Talzenna) - the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curat

Talazoparib (Talzenna) - the treatment of adult patients with a deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated human epidermal growth factor receptor 2 (HER2)-negative locally advanced (not amenable to curat Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact

2020 Health Canada - Drug and Health Product Register

15. Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer

Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer Breast Cancer: Community Health Workers | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) April 2019 Audience Adults Low-income Population Women Setting Clinical/Health Systems Community Home Strategy Health (...) Education Screening Cancer Screening: Interventions Engaging Community Health Workers – Breast Cancer Tabs Snapshot Summary of CPSTF Finding The interventions that engage community health workers to increase screening for breast cancer by mammography. Evidence shows these interventions increase breast cancer screening rates when community health workers deliver them independently or as part of an implementation team. Interventions that engage community health workers to increase breast cancer screening

2020 Community Preventive Services Task Force

16. Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer

Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer Colorectal Cancer: Community Health Workers | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) April 2019 Audience Adults Low-income Population Setting Clinical/Health Systems Community Home Strategy Health (...) Education Screening Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer Tabs Snapshot Summary of CPSTF Finding The interventions that engage community health workers to increase screening for colorectal cancer by colonoscopy or fecal occult blood test [FOBT]. Evidence shows these interventions increase colorectal cancer screening rates when community health workers deliver them independently or as part of an implementation team. Interventions that engage community

2020 Community Preventive Services Task Force

17. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial Full Text available with Trip Pro

Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial Testosterone Replacement in Young Male Cancer Survivors: A 6-month Double-Blind Randomised Placebo-Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable (...) your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Randomized Controlled Trial PLoS Med Actions , 16 (11), e1002960 2019 Nov 12 eCollection Nov 2019 Testosterone Replacement in Young Male Cancer Survivors: A 6-month Double-Blind Randomised Placebo-Controlled Trial , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology and Metabolism

2020 EvidenceUpdates

18. Cancer Screening: Interventions Engaging Community Health Workers – Cervical Cancer

Cancer Screening: Interventions Engaging Community Health Workers – Cervical Cancer Cervical Cancer: Community Health Workers | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) April 2019 Audience Adults Low-income Population Women Setting Clinical/Health Systems Community Home Strategy Health (...) Education Screening Cancer Screening: Interventions Engaging Community Health Workers – Cervical Cancer Tabs Snapshot Summary of CPSTF Finding The interventions that engage community health workers to increase screening for cervical cancer by Pap smear. Evidence shows these interventions increase cervical cancer screening rates when community health workers deliver them independently or as part of an implementation team. In addition, economic evidence shows these interventions are cost-effective

2020 Community Preventive Services Task Force

19. Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer

Fam-trastuzumab deruxtecan-nxki (Enhertu) - metastatic breast cancer Drug Approval Package: ENHERTU ENHERTU " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ENHERTU Company: Daiichi Sankyo, Inc. Application Number: 761139 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

20. Enfortumab vedotin-ejfv (Padcev) - refractory bladder cancer

Enfortumab vedotin-ejfv (Padcev) - refractory bladder cancer Drug Approval Package: PADCEV enfortumab vedotin-ejfv U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: PADCEV enfortumab vedotin-ejfv Company: Astellas Pharma US, Inc. Application Number: 761137 Approval Date: 12/08/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application

2020 FDA - Drug Approval Package